Answers are grounded in this paper and cite their sources.
Small interfering RNA (siRNA) achieves significant clinical success in treating liver-related diseases. However, its broader application remains constrained by the low productiveness of extrahepatic delivery owing to the endosomal escape bottleneck. Here, we reported a fluorescein (FAM)-binding bispecific antibody (Fab-scFv-Fc bsAb) that can recruit one molecule of FAM-labeled siRNA and deliver productively to skin tissues by light-activatable silencing. Resembling the canonical antibody−siRNA conjugate, bsAb forms a stable monodisperse scaffold with siRNA and enables specific delivery to cells that express the corresponding antigen. Upon light radiation, the FAM dye acts as a photosensitizer and promotes the cytosolic release of siRNA from endosomes, which enhances the silencing activity > 10 times stronger than the control without photostimulation. Over 90% of target mRNA expression could be knocked down after irradiation by light with intensity comparable to the midday sunlight (100 k lux) for 5 min. In vivo, bsAb extends the siRNA half-life to 26 h and supports the productive delivery to the subcutaneous tumor tissue, where light is accessible for activation. With the spatiotemporal control of silencing, this antibody offers a useful siRNA delivery solution to extrahepatic skin tissues.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: